November 6, 2024 7:55am

Also, with a win for the House and Senate to stimulate economic, regulatory and legislative priorities

Earnings today: Ionis Pharmaceuticals (IONS), Lenz Therapeutics (LENZ)

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

Never leave an investor uninform

RegMed Investors (RMi) Closing Bell: earnings, election voting and the end of talking heads … https://www.regmedinvestors.com/articles/13685

RegMed Investors (RMi) Research Note: Q3/24 earnings reporting dates, net losses, cash positions, revenue and runway outcomes … https://www.regmedinvestors.com/articles/13441

RegMed Investors (RMi) - Q3/24 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628

 

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

 

Wednesday: The pre-open Dow futures are UP +3.18% or (+1,346 points), the S&P futures are UP +2.25% or (+130 points) and the Nasdaq futures are UP +1.64% or (+334 points)

  • Futures skyrocket on Wednesday post-election night, 11/6
  • European markets were positive,
  • Asia-Pacific markets were mixed

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Tuesday: The Dow closed UP +427.28 points or +1.02%, the S&P closed UP +70.07 points or +1.23% while the Nasdaq closed UP +259.19 points or +1.43%

  • Tuesday’s advance/decline line ended with a positive close at the close of 25 incliner, 8 decliners and 2 flats
  • Stocks tied to a Donald Trump presidential election victory soared in premarket trading Wednesday as the former president neared a return to the White House.

Economic Data Docket: MBA Mortgage Applications, the week ended Nov. 1 (-0.1% prior); S&P Global US services PMI, October final (55.3 expected, 55.3 prior); S&P Global US composite PMI, October final (54.3 prior)

 

Q4/24: November 1 negative and 2 positive closes

  • October: 8 positive and 15 negative closes

Q3/24:

  • September – 10 positive and 10 negative close
  • August – I neutral, 10 positive and 11 negative closes
  • July: 1 market holiday. 1 day off, 6 negative, 1 neutral and 12 positive closes

 

Earnings: Ultragenyx Pharmaceuticals (RARE) reported Q3/24 earnings, a net loss of -$133.5 M or -$1.40 per share, revenue was $139.4 M with a 2027 runway and a cash position of $825 M.

 

Companies in my headlights – It’s your decision; I provide ideas and context 

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Let them roll as sector spikes with the market’s dramatic ascension.

 

Although, I would consider …

BUY - ALNY, closed -$4.88, aftermarket was +$1.22 or +0.46%

  • AXGN closed +$0.76, aftermarket was +$0.29 or +1.94%

SELL - RARE closed +$1.12 -aftermarket was -$0.58 or -1.11%

         - VCEL closed +$0.38, aftermarket -$0.80 or -1.79%

         - MESO closed +$0.43, aftermarket -$0.43 or -4.90%

         - VERV closed +$0.33, after market -$0.18 or -2.82%

         - BLFS closed +$0.36, aftermarket -$0.22 or -0.85

 

The BOTTOM LINE: A win, investors had little to complain about during Trump's first term in the Oval Office.

The iconic Dow, the S&P 500 and the Nasdaq respectively gained 56%, 67%, and 138%.

Back to Earnings season … Investors can NOT ignore the depreciated share pricing of the sector.

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.